House panel limits CE research
This article was originally published in The Gray Sheet
In a last-minute markup session on health reform legislation before breaking for its August recess, the House Energy and Commerce Committee agreed by voice vote to limits on comparative effectiveness research. One amendment, offered by Rep. Mike Rogers, R-Mich., states that the research cannot be used to deny or ration care. A second amendment from Rep. Phil Gingrey, R-Ga., specifies that CMS cannot base coverage decisions on federally funded clinical comparative effectiveness research. At press time, markup on the bill was expected to be completed, and the entire package approved by the panel, before the House recessed. The Senate Finance Committee said July 31 it will not vote on its version of health reform until the Senate returns from its recess in September
You may also be interested in...
Device firms have spent heavily on members of Congress seeking to slow the progress and limit the scope of health care reform legislation, according to lobbying contribution records maintained by the clerk of the House and secretary of the Senate
Amendments to ban reduced payments for pain treatments and make screenings for aneurysms a priority are just two provisions added to a health reform bill during the House Energy and Commerce Committee's marathon mark-up sessions July 30 and 31
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.